New therapies to improve treatment for acute myeloid leukemia
Multi-functional cellular therapies to overcome tumor heterogeneity and limit toxicity in acute myeloid leukemia
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10913981
This study is exploring new ways to treat acute myeloid leukemia (AML) by using special immune cells and antibodies to create a more targeted therapy that could help patients feel better and lower the chances of the cancer coming back.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10913981 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative cellular therapies to treat acute myeloid leukemia (AML), a type of blood cancer with a low survival rate. The approach aims to address two major challenges in AML treatment: the lack of specific targets for therapy and the variability of the cancer cells within patients. By utilizing advanced technologies, including engineered T-cells and bispecific antibodies, the research seeks to create a more effective treatment that minimizes side effects and improves patient outcomes. Patients may benefit from a therapy that targets the cancer more precisely and reduces the risk of relapse.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who are seeking new treatment options.
Not a fit: Patients with other types of blood cancers or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results with similar cellular therapy approaches in treating blood cancers, indicating potential for success in this area.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KASAP, CORYNN — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: KASAP, CORYNN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.